LabGenius Therapeutics

LabGenius Therapeutics is a company developing next-generation therapeutic antibodies using its closed-loop machine learning platform.

The platform integrates AI, robotic automation and high-throughput experimentation to co-optimise multispecific antibodies across potency, selectivity and manufacturability simultaneously.

Its internal pipeline focuses on selectivity-enhanced T-cell engagers for solid tumours, with lead asset LGTX-101 targeting Nectin-4.

The company operates a hybrid model combining pharma partnerships, including a second Sanofi collaboration in 2025, alongside a wholly-owned pipeline.